MS&L wins Glaxo diabetes work

Glaxo Wellcome has handed PR for the UK launch of a new diabetes product Romozin (troglitazone) to Manning Selvage and Lee, following a five-way pitch.

Glaxo Wellcome has handed PR for the UK launch of a new diabetes

product Romozin (troglitazone) to Manning Selvage and Lee, following a

five-way pitch.



The campaign,which is believed to carry a six-figure fee, will target

general practitioners and healthcare professionals through the medical

press and the medical and science pages of the national press.



MS&L will be responsible for launching the product and helping to

re-establish Glaxo Wellcome in the diabetes field.



’Glaxo were involved in the diabetes field in the 1970s as an insulin

supplier, but it has little presence at the moment,’ said a Glaxo

spokesman.



Romozin, the first of a new class of drugs, treats non-insulin dependent

diabetes mellitus. ’If you don’t treat non-insulin dependent diabetes

properly there are a lot of related problems, like heart disease,

amputations and obesity,’ said Henrietta Noyes, director of healthcare

at MS&L.



’The main message stems from Glaxo Wellcome’s belief that diabetes is an

under-estimated illness,’ said the Glaxo spokesman.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in